Cargando…
P475: EMERGING LEUKEMIA ASSOCIATED IMMUNOPHENOTYPES (LAIPS) IN BONE MARROW OF ACUTE MYELOID LEUKEMIA PATIENTS AFTER INTENSIVE CHEMOTHERAPY.
Autores principales: | Lam Ngai, Lok, Hanekamp, Diana, Kelder, Angèle, Scholten, Willemijn J., Carbaat - Ham, Jannemieke, Snel, Alexander N., Bachas, Costa, Tettero, Jesse, van der Velden, Vincent, Slomp, Jennichjen, Hobo, Willemijn, Breems, Dimitri, Fischer, Thomas, Tore Gjertsen, Bjorn, Griškevičius, Laimonas, Juliusson, Gunnar, Maertens, Johan, Manz, Markus, Pabst, Thomas, Passweg, Jakob, Porkka, Kimmo, Valk, Peter, Gradowska, Patrycja, Löwenberg, Bob, de Leeuw, David, van de Loosdrecht, Arjan, Ossenkoppele, Gert, Cloos, Jacqueline |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429281/ http://dx.doi.org/10.1097/01.HS9.0000968808.37084.f7 |
Ejemplares similares
-
Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survival
por: Tettero, Jesse M., et al.
Publicado: (2023) -
Prospective validation of the prognostic relevance of CD34(+)CD38(–) AML stem cell frequency in the HOVON-SAKK132 trial
por: Ngai, Lok Lam, et al.
Publicado: (2023) -
P432: VALIDATION OF LIMIT OF QUANTIFICATION APPROACH BASED FLOW CYTOMETRY FOR MEASURABLE RESIDUAL DISEASE ASSESSMENT IN ACUTE MYELOID LEUKEMIA IN THE HOVON-SAKK-132 TRIAL
por: Tettero, Jesse, et al.
Publicado: (2023) -
Concordance in measurable residual disease result after first and second induction cycle in acute myeloid leukemia: An outcome- and cost-analysis
por: Tettero, Jesse M., et al.
Publicado: (2022) -
Immunophenotypic Detection of Measurable Residual (Stem Cell) Disease Using LAIP Approach in Acute Myeloid Leukemia
por: Zeijlemaker, Wendelien, et al.
Publicado: (2019)